LECT-2 Amyloidosis: What Do We Know?

ABSTRACT

Amyloidosis is a rare group of diseases characterized by the abnormal folding of proteins and extracellular deposition of insoluble fibrils. It can be localized to one organ system or can have systemic involvement. The kidney is the most common organ to be involved in systemic amyloidosis often leading to renal failure and nephrotic syndrome. The two most common types of renal amyloidosis are immunoglobulin light chain-derived amyloidosis (AL) and reactive amyloidosis (AA). A novel form of amyloidosis (ALECT2) derived from leukocyte chemotactic factor 2 (LECT-2) and primarily involving the kidneys was first described by Benson et al in 2008. The liver was subsequently identified as the second most common organ involved in ALECT2 amyloidosis. LECT-2 is a unique protein that can form amyloid deposits even in its unmutated form. Patients with ALECT2 present with minimal proteinuria in contrast to other forms of amyloidosis especially AL and AA. They may present with slightly elevated serum creatinine. Nephrotic syndrome and hematuria are rare. ALECT2 can be found in association with other types of amyloidosis as well as malignancies or autoimmune diseases. ALECT2 may be confused with amyloidosis associated with light and heavy-chain monoclonal gammopathy if the immunofluorescence is positive with anti-light chain and anti-AA sera. The other organs involved are the duodenum, adrenal gland, spleen, prostate, gall bladder, pancreas, small bowel, parathyroid gland, heart, and pulmonary alveolar septa, but consistently uninvolved organs included brain and fibro adipose tissue. A renal biopsy along with characteristic features found in immunohistochemistry and mass spectrometry is diagnostic of ALECT2. ALECT2 should be suspected when all markers for AL and AA are negative. Proper diagnosis of ALECT2 can determine the need for supportive care versus more aggressive interventions.

INTRODUCTION 

Amyloidosis represents a group of diverse disorders characterized by abnormal folding of proteins and extracellular deposition of insoluble fibrils. There are over known 36 proteins that can form amyloid. The deposition of these abnormal amyloid fibrils in various tissues can ultimately lead to organ damage. Amyloidosis can manifest locally or systemically but can affect any organ. The most common organs involved in systemic amyloidosis include the skin, heart, liver, renal, digestive tract, and nervous system. However, the kidney is probably the most commonly involved organ and when affected can result in nephrotic syndrome and renal failure.1 2 Historically, the two most common types of amyloid disorders leading to renal involvement are AL and AA. Some hereditary forms of amyloidosis are derived from fibrinogen A, apolipoprotein, gelsolin, and lysozyme affecting the kidney, but these are exceedingly rare. In 2008, Benson et al reported a case in which a patient presenting with nephrotic syndrome and renal failure leading to dialysis was found to have isolated deposition of amyloid in the glomerulus.1 There were no other organs other than the kidney affected and immunohistochemistry (IHC) of the renal biopsies for known abnormal amyloid proteins was negative. Further biochemical analysis of the fibrils confirmed that they represented a novel renal amyloid protein which was identified as leukocyte chemotactic factor 2 (LECT-2). Amyloidosis restricted to the kidney is not common and this new renal predominant disorder was termed ALECT2. Subsequent reports demonstrated that among previously unidentified and unclassified renal-limited amyloidosis, ALECT2 was common.2 The deposition of LECT-2 was different from other types of renal amyloid in demonstrating zoophilia within all compartments of the kidney including mesangium, glomerular basement membrane, interstitium, arterioles, and arteries.2

According to relevant studies,cistanche is a traditional Chinese herb that has been used for centuries to treat various diseases. It has been scientifically proven to possess anti-inflammatory, anti-aging, and antioxidant properties. Studies have shown that cistanche is beneficial for patients suffering from kidney disease. The active ingredients of cistanche are known to reduce inflammation, improve kidney function and restore impaired kidney cells. Thus, integrating cistanche within a kidney disease treatment plan can offer great benefits to patients in managing their condition. Cistanche helps to reduce proteinuria, lowers BUN and creatinine levels, and decreases the risk of further kidney damage. In addition, cistanche also helps reduce cholesterol and triglyceride levels which can be dangerous to patients suffering from kidney disease. Cistanche's antioxidant and anti-aging properties help to protect the kidneys from oxidation and damage caused by free radicals. This improves kidney health and reduces the risks of developing complications. Cistanche also helps to boost the immune system, which is essential in fighting off kidney infections and promoting kidney health. By combining traditional Chinese herbal medicine and modern western medicine, those suffering from kidney disease can have a more comprehensive approach to treating the condition and improving their quality of life. Cistanche should be used as part of a treatment plan but is not to be used as an alternative to conventional medical treatments.

Click On Cistanche Deserticola Supplement 

Ask for more:

 david.deng@wecistanche.com  WhatApp:86 13632399501

Although initially it was identified as renal limited amyloidosis, recent reports demonstrate the involvement of the liver as well as subclinical involvement of the spleen, bowel, adrenal glands, lung, prostate, gallbladder, pancreas, and parathyroid gland.3 It appears to spare nerves and fat but renal manifestations predominate. The molecular basis and pathogenesis are unclear and not well defined but ALECT2 has a better prognosis than AL or AA. The initial reports of ALECT2 suggested that it preferentially affects patients with Hispanic ethnicity particularly Mexicans and Mexican-Americans in the southwestern part of the USA. However, subsequent reports documented the disease in Punjabis, First Nations peoples in British Columbia, Egyptians, Chinese of Han ethnicity, and Native Americans as well.3 The limitation of ALECT2 in non-Caucasian populations remains unclear.

Pathophysiology 

LECT-2 was first identified in 1996 by Yamagoe et al and recognized as a chemotactic factor for neutrophils.4 Lu et al subsequently demonstrated that treatment with LECT-2 improved protective immunity via enhancement of macrophage functions in septic mice.5 It is now clear that it is a versatile protein involved in chemotaxis, cell proliferation, inflammation, immunomodulation, and carcinogenesis.6 The protein consists of 133 amino acids, and three intramolecular disulfide bonds which bind a single Zn molecule and its gene located in chromosome 5q31.1-q32.7 This chromosome harbors a cluster of genes involved in immune-regulatory cytokines.

Among patients with ALECT2, there are several polymorphisms1 8–14 and a few mutations15 16 that have been identified. A polymorphism of the G nucleotide at position 172 of the LECT-2 gene has been noted, especially in patients from Latin America, which is associated with renal amyloidosis but the polymorphism is insufficient for disease progression and an identified second hit is suspected.17 Another single nucleotide polymorphism in the LECT-2 gene is Val58lle which is frequently seen in renal ALECT2.17 A recent report suggests that removal of LECT-2’s single-bound Zn appears to be necessary for fibril formation.18 Thus, it is postulated that the removal of zinc together with an associated mutation leads to abnormal LECT-2 and results in ALECT2.

The LECT-2 protein is produced in the liver and hepatocytes show diffuse immune staining of LECT-2 within their cytoplasm.19–21 LECT-2 is a hepatocyte that gets increased in response to the deposition of fat inside the liver. Elevated LECT-2 mRNA levels have been found in obese patients with hepatic steatosis.22 Aggregation of abnormal circulating LECT-2 protein results in amyloidosis. The exact pathophysiology is unclear, but a combination of genetic factors or mutations in conjunction with environmental factors (obesity) may result in the upregulation of LECT-2 production among hepatocytes. The elevated unstable/misfolded LECT-2 protein in combination/interaction with other circulating factors such as components of the extracellular matrix ultimately leads to abnormal fibril production. These abnormal LECT-2 fibrils get deposited in the interstitium of the kidney and liver and impede their physiologic functions.23 There is an association between LECT-2 and the pathophysiology of diseases among a variety of different organ systems including the renal, gastrointestinal, hepatic, skeletal, immune system, endocrine and metabolic, oncology, pulmonary, and vascular.17

Clinical manifestations of renal ALECT2 amyloidosis 

The hallmark of another non-ALECT2 amyloid disease such as AL or amyloidosis of the transthyretin (ATTR) is the multi-organ involvement, which raises the suspicion of a systemic illness. In these types of amyloidosis, there is frequent cardiac, nervous, renal, dermatological, and other organ system involvement. Among such amyloidosis entities, the need for a kidney biopsy is less.23 The diagnosis of amyloid deposition in AL or ATTR can be made via the skin, bone marrow, or cardiac biopsy or non-invasive tests such as serum protein electrophoresis or bone scan that play an important role in diagnosis. Once amyloid is identified, then it can be further classified via liquid chromatography/ mass spectrometry (LC/MS).

However, in ALECT2, there is the very minimal cardiac, nervous system, skin, or other organ involvement, but renal and to a lesser degree hepatic pathology is the likely presenting clinical feature. ALECT2 was first identified in 2008 in a patient with chronic kidney disease (CKD) secondary to nephrotic syndrome with no other clinical organ involvement.1 Later, many cases describing the hepatic involvement were also reported and some autopsy studies documented ALECT2 deposition in other organs. Nevertheless, renal pathology remains the most common clinical presentation as the sole clinical feature. In the USA, there is a strong ethnic bias for renal ALECT2 in contradistinction to another systemic amyloidosis with 88%%–92% of cases reported among Hispanics, specifically Mexican-Americans.23 The typical presentation in the USA is an elderly Hispanic patient presenting with chronic renal insufficiency with or without proteinuria. It is not unique to this ethnic group as ALECT2 has been described in Punjabis, First Nations people in British Columbia, Arabs, Israelis, and Native Americans.23

Three large series of ALECT2-documented patients, totaling 144 cases, have been previously reported that provided the summary highlighting and elucidating the renal manifestations.9–11 23 The median age at diagnosis is 69 years old, with only 5 patients less than 50 years of age at diagnosis. Men and women are equally affected and there is minimal presence of a family history of amyloidosis. Patients typically present with isolated CKD with a mean serum creatinine at diagnosis ranging from 2.8 to 3 mg/dL. The serum creatinine at the time of diagnosis is not necessarily proportional to total renal amyloid load or with a degree of amyloid in glomeruli, interstitium, or vessels but may correspond to the percentage of global glomerulosclerosis, tubular atrophy/interstitial fibrosis, and arteriosclerosis.10

An interesting feature of renal ALECT2 is that proteinuria is minimal in comparison with other forms of amyloidosis, especially AL or ATTR. Nephrotic range proteinuria was noted in only 33% of 72 patients in the series by Said et al and lacking altogether in 21%.10 In the series by Larsen et al, proteinuria was noted in 33% and nephrotic range proteinuria in only 23%.9 The bland urinary sediment may reflect early glomerular involvement by amyloid that reflects a more characteristic feature of renal ALECT2.24 When nephrotic range proteinuria is present in ALECT2, it is important to consider that it may be due to a concomitant underlying nephropathy9 like diabetic glomerulosclerosis or IgA nephropathy.10 It may have concurrent membranous glomerulopathy, acute tubular injury, interstitial nephritis, or arterionephrosclerosis, or podocytopathy/nephrotic syndrome.25 26 Microhematuria is uncommon. The most common associated comorbidities are chronic hypertension and diabetes. The worsening of renal failure to end-stage renal disease ranges from approximately 30% to 40% of cases.9 10 ALECT2 can be found in association with other types of amyloidosis like immunoglobulin λ light chain amyloidosis,27 plasma cell dyscrasia,10 or membranous nephropathy,28 some type of carcinoma (kidney, bladder, prostate, uterine and breast) or history of autoimmune disease.10

A kidney biopsy conducted to investigate the cause of abnormal kidney function demonstrating amyloid deposition is the first clue for consideration of ALECT2. IHC can be conducted with commercially available antibodies. ALECT2 kidney deposition is strongly congophilic showing apple-green birefringence under polarized light.9 Along with Congo red-positive amyloid deposits, there are some other notable distinguishing pathologic characteristics. Renal ALECT2 demonstrates preferential diffuse cortical interstitial involvement in contrast to other amyloid disorders which affect the medullary interstitium.10 In contrast to AL and AA with prominent glomeruli and vessel amyloid deposition, the glomerular and vascular amyloid deposits in ALECT2 may be absent or may range from mild to marked staining.10 Immunofluorescence analysis, which is part of routine work-up for amyloidosis, is frequently negative in ALECT2 although false-positive staining for IgG may occur on rare occasions.10 Therefore, LC/MS proteomics along with the IHC-based approach becomes extremely helpful for the identification of ALECT2 and differentiating it from other forms of amyloidosis. LC/MS remains the most sensitive and specific method to diagnose ALECT2 and other forms of amyloidosis to date.

There is a possibility of missing ALECT2 as contributing to the renal pathology due to the confounding comorbidities seen in these patients. Thus, nephrologists and pathologists should have a higher degree of suspicion for ALECT2. This is especially true in older individuals of Mexican origin or the other reported ethnicities who present with CKD with absent or mild proteinuria. A Congo red stain should be performed and congophilic differences between ALECT2 and other amyloidosis subtypes should be appreciated. If ALECT2 is the predominant pathology, there is no known current treatment and early detection of ALECT2 may avoid the initiation of unnecessary or potentially harmful therapies. Additional research on the natural history and potential therapies of ALECT2 disease is needed. The pioneer cases or case series of ALECT2 reported over the last decade have been enlisted in table 1.

Hepatic ALECT2 amyloidosis 

Interestingly, the identification of ALECT2 and its role in renal pathology has led to the observation of LECT-2 playing a role in liver health, disease, and regeneration as well. As mentioned previously, the synthesis of LECT-2 protein from hepatocytes is regulated by β-catenin and acts as versatile chemokine.29 30 In an elegant study, Takata et al proposed a schema of the effects of LECT-2 on liver inflammation.22 They demonstrated elevated LECT-2 protein levels are found in response to high fat intake and trigger lipopolysaccharide-stimulated C-Jun N-terminal kinase phosphorylation which macrophage-mediated inflammation of liver tissue. This transforms minor hepatic steatosis into non-alcoholic steatohepatitis. These findings suggest that treatment targeting the LECT-2 protein could help in disintegrating hepatic steatosis from inflammation. The liver is also a commonly involved organ by ALECT2 and compromises between 60% and 90% of cases of systemic amyloidosis.31

Mereuta et al described and evaluated 130 cases of unclassified hepatic amyloidosis that were identified histologically.11 Using LC/MS technique, AL was confirmed to be the most frequent etiology of amyloidosis while ALECT2 accounted for 25% of cases. Before this report, ALECT2 was not a known cause of hepatic amyloidosis. Like the original renal ALECT2 reports, this series from the USA also showed ethnic predominance among Hispanics in the hepatic ALECT2 cases. The pathologic characteristics of hepatic ALECT2 are different and unique from those of AL. In Mereuta et al’s study, all the hepatic ALECT2 specimens demonstrated globular amyloid deposits localized along the periportal parenchyma or at the periphery of the portal triad and around central venules.11 These characteristic features of the globular pattern of ALECT2 deposits contrast with hepatic AL which leads to perisinusoidal amyloid deposition.

The clinical significance of making the correct diagnosis of hepatic ALECT2 is important to prevent misdiagnosis as AL, AA, or ATTR amyloidosis which has different therapeutic options and clinical courses. Hepatic ALECT2 has no therapeutic options available but the clinical course may be more indolent like renal ALECT2. However, there are reports of hepatic ALECT2 leading to cirrhosis, portal hypertension, and esophageal bleeding suggesting that hepatic ALECT2 may be an under-reported entity. 32 Since LECT-2 is synthesized in the liver, it has been noted that LECT-2 levels decrease in liver failure and increase when liver function recovers.33 Thus, the serum LECT-2 levels may serve as a prognostic indicator in acute liver failure and LECT-2 may participate in liver regeneration, but further studies are needed. Okabe et al have evaluated the role of LECT-2 as a potential biomarker in hepatocellular carcinoma (HCC).34 LECT-2 levels were found to be elevated in HCC as compared with patients with cirrhosis or healthy controls. There is one report of intrahepatic cholangiocarcinoma with concomitant ALECT2.35

Other organ system involvement 

ALECT2 is likely a systemic amyloid disease however renal manifestations dominate the clinical picture. The liver is commonly involved and few reports link it with abnormal liver pathology.11 32 36 Most of the other organ involvement is subclinical. A study from the Mayo Clinic including 120 patients with ALECT2 diagnosed by LC/MS found that 72 patients had a kidney, 36 liver, 5 spleens, 3 prostate, and 1 each of gallbladder, pancreas, small bowel, and parathyroid gland involvement.10 In most ALECT2 cases reported in the past, kidney biopsy was due to a variety of renal abnormalities, but none had clinically evident extrarenal organ involvement. In the series of hepatic ALECT2 reported by Mereuta et al, none of the patients had clinical extrahepatic organ involvement.11 An autopsy series from New Mexico found that ALECT2 is common among Hispanics in New Mexico and likely represents an underdiagnosed etiology of CKD in this population.37 In this series, amyloid deposits were observed in a consistent pattern primarily involving the kidneys, liver, spleen, adrenal glands, and lungs. None had deposition in the cardiac myocardium, brain, skin, or fibro adipose tissue. Only one case has been reported in the literature describing cardiac ALECT238 and another reported a rare presentation of pulmonary-renal syndrome.39 It is conceivable that other clinically significant organ involvement aside from renal or hepatic is under-recognized. Given the sparsity of skin or fat involvement, it is highly unlikely that less invasive procedures like a biopsy of the skin or fat pad will be useful in documenting systemic ALECT2.

Diagnosis and treatment

Non-ALECT2 amyloid disorders frequently have a cardiac, nervous system, fat, or skin involvement in addition to renal dysfunction. In a patient where renal dysfunction or liver appears to be the sole clinical manifestation of amyloidosis, ALECT2 should be strongly considered. The typical presentation in the USA is an elderly Hispanic patient presenting with CKD with or without proteinuria for whom a concomitant diagnosis of diabetes or hypertension is not suspected to be a major contributing cause of renal dysfunction. A renal biopsy should be conducted for the evaluation of amyloid when indicated. ALECT2 should be suspected when markers for the other systemic amyloid disorders (AA, AL, and ATTR) are negative. Circulating LECT-2 levels are not useful in screening. There is one report describing the use of florbetapir radiotracer-based positron emission tomography/computed tomography (PET/CT) demonstrating remarkable uptake in the kidney in a patient with biopsy-confirmed ALECT2.40 Unlike AL or ATTR amyloid, there was no uptake to the heart but extremely active uptake to the involved ALECT2 kidney was noted. However, further studies are needed to make it more clear that florbetapir PET/CT can be used as a screening test.

On histopathology, ALECT2 is strikingly congophilic and demonstrates preferential diffuse cortical interstitial involvement, and less medullary involvement, with variable glomerular and vascular amyloid deposition.9 This differentiates ALECT2 from other forms of amyloidosis with characteristic morphologic patterns such as predominant medullary involvement in apolipoprotein A-IV associated amyloidosis41 and predominant glomerular deposition in hereditary fibrinogen amyloidosis.42 Patients with ALECT2 with concomitant nephrotic syndrome must be alert for the possibility of concurrent podocytopathy and electron microscopy must be performed, especially if clinical findings are inconsistent with the affected kidney compartment.26

The liver ALECT2 deposition, like the renal ALECT2, has a characteristic histologic pathology. ALECT2 liver deposits are noted to preferentially surround the central veins and along the periphery of the portal tracts with a very distinctive globular appearance. This contrasts with AL deposits which frequently exhibit a perisinusoidal distribution pattern.43 LC/MS proteomics is an excellent tool to subtype amyloidosis. It remains the most sensitive and specific method to differentiate ALECT2 from other forms of amyloidosis to date.

A critical need for accurate diagnosis, identification, and differentiation of ALECT2 from other systemic amyloidosis is to prevent unnecessary and potentially harmful treatments. For example, if ALECT2 is misdiagnosed as amyloidosis caused by a subtle plasma cell dyscrasia, it may result in the administration of chemotherapy. Unfortunately, at present, there is no specific treatment for ALECT2 in contrast to ATTR and AL amyloid. The treatment of ALECT2 is mainly supportive in nature and although the natural history is not well defined, it appears to be more indolent in the course than AL or ATTR. A few reports have demonstrated donor-derived ALECT2 deposits in transplanted allografts which did not resolve over time but remained stable with no interference of allograft function.44 45 In instances where ALECT2 coexists with clinically significant IgA nephropathy and nephrotic syndrome, there is a benefit of treating with chemotherapy and/or steroids which are effective for the IgA nephropathy.10

Summary 

Since its original description 13 years back, we now know that ALECT2 is a common amyloid entity. It has an ethnic predisposition with predominantly interstitial renal distribution, usually misdiagnosed due to the absence of monoclonal gammopathy, the absence of a family history of amyloidosis, the rarity of extrarenal involvement, and the relative absence of marked proteinuria. It is still likely to be unrecognized and underappreciated. We hope that additional research on the natural history and potential therapy for ALECT2 will be forthcoming in the future.

Contributors 

All authors have contributed to the manuscript and agreed with the final version of the manuscript. The final authorship contribution statement is as follows: BKM and JB are credited with substantial contributions to the design of the work, literature review of all the sections discussed, revision of critically important intellectual content, and final content writing. EC contributed to the initiation of the idea, revision of critically important intellectual content, and agreement of accountability for all parts of the work. CC and SE contributed to the revision of the manuscript and the agreement of accountability for all parts of the work.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer-reviewed.

REFERENCES

1 Benson MD, James S, Scott K, et al. Leukocyte chemotactic factor 2: a novel renal amyloid protein. Kidney Int 2008;74:218–22. 

2 Larsen CP, Walker PD, Weiss DT, et al. Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies. Kidney Int 2010;77:816–9. 

3 Picken MM. The pathology of amyloidosis in classification: a review. Acta Haematol 2020;143:322–34. 

4 Yamagoe S, Yamakawa Y, Matsuo Y, et al. Purification and primary amino acid sequence of a novel neutrophil chemotactic factor LECT2. Immunol Lett 1996;52:9–13. 

5 Lu X-J, Chen J, Yu C-H, et al. Lect2 protects mice against bacterial sepsis by activating macrophages via the CD209a receptor. J Exp Med 2013;210:5–13. 

6 Ong HT, Tan PK, Wang SM, et al. The tumor suppressor function of LECT2 in human hepatocellular carcinoma makes it a potential therapeutic target. Cancer Gene Ther 2011;18:399–406. 

7 Yamagoe S, Kameoka Y, Hashimoto K, et al. Molecular cloning, structural characterization, and chromosomal mapping of the human LECT2 gene. Genomics 1998;48:324–9. 

8 Murphy CL, Wang S, Kestler D, et al. Leukocyte chemotactic factor 2 (LECT2)- associated renal amyloidosis: a case series. Am J Kidney Dis 2010;56:1100–7. 

9 Larsen CP, Kossmann RJ, Beggs ML, et al. Clinical, morphologic, and genetic features of renal leukocyte chemotactic factor 2 amyloidosis. Kidney Int 2014;86:378–82. 

10 Said SM, Sethi S, Valeri AM, et al. Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. Kidney Int 2014;86:370–7.

11 Mereuta OM, Theis JD, Vrana JA, et al. Leukocyte cell-derived chemotaxis 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. Blood 2014;123:1479–82. 

12 Gödecke VA, Röcken C, Steinmüller-Magin L, et al. Mixed leukocyte cell-derived chemotaxis 2 and amyloid renal amyloidosis in a Kazakh-German patient. Clin Kidney J 2017;10:266–8. 

13 Rezk T, Gilbertson JA, Rowczenio D, et al. Diagnosis, pathogenesis, and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis. Nephrol Dial Transplant 2018;33:241–7. 

14 Ortega Junco E, Sánchez González C, Serrano Pardo R, et al. LECT2- associated renal amyloidosis (ALECT2): a case report. Nefrologia 2018;38:558–60. 

15 Chakrabarti A, Samal P, Chakrabartty J. Amyloidosis: the newer discovered ALECT2 associated with der7q add(7). J Clin Diagn Res 2016;10:ED04–5. 

16 Law S, Gillmore J, Gilbertson JA, et al. Karyomegalic interstitial nephritis with a novel FAN1 gene mutation and concurrent ALECT2 amyloidosis. BMC Nephrol 2020;21:74. 

17 Slowik V, Apte U. Leukocyte cell-derived Chemotaxin-2: its role in pathophysiology and future in clinical medicine. Clin Transl Sci 2017;10:249–59. 

18 Ha J-H, Tu H-C, Wilkens S, et al. Loss of bound zinc facilitates amyloid fibril formation of leukocyte-cell-derived chemotaxis 2 (LECT2). J Biol Chem 2021;296:100446. 

19 Uchida T, Nagai H, Gotoh K, et al. Expression pattern of a newly recognized protein, LECT2, in hepatocellular carcinoma and its premalignant lesion. Pathol Int 1999;49:147–51. 

20 Yamagoe S, Akasaka T, Uchida T, et al. Expression of a neutrophil chemotactic protein LECT2 in human hepatocytes revealed by immunochemical studies using polyclonal and monoclonal antibodies to a recombinant LECT2. Biochem Biophys Res Commun 1997;237:116–20.

21 Yamagoe S, Mizuno S, Suzuki K. Molecular cloning of human and bovine LECT2 having a neutrophil chemotactic activity and its specific expression in the liver. Biochim Biophys Acta 1998;1396:105–13. 

22 Takata N, Ishii K-A, Takayama H, et al. LECT2 as a hepatocyte links liver steatosis to inflammation via activating tissue macrophages in NASH. Sci Rep 2021;11:555. 

23 Nasr SH, Dogan A, Larsen CP. Leukocyte cell-derived chemotaxis 2-associated amyloidosis: a recently recognized disease with distinct clinicopathologic characteristics. Clin J Am Soc Nephrol 2015;10:2084–93.

24 Holanda DG, Acharya VK, Dogan A, et al. Atypical presentation of atypical amyloid. Nephrol Dial Transplant 2011;26:373–6. 

25 Larsen CP, Ismail W, Kurtin PJ, et al. Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a common form of renal amyloidosis among Egyptians. Mod Pathol 2016;29:416–20. 

26 Valdés-Lagunes DA, Méndez-Pérez RA, de la Cruz MA, et al. Nephrotic syndrome in the setting of LECT2 amyloidosis: take a look at the podocyte. Clin Nephrol 2020;94:266–70. 

27 An N, Chen SL, Li X. [A case report of immunoglobulin λ light chain amyloidosis combined with leukocyte cell-derived chemotaxis-2 amyloidosis]. Zhonghua Nei Ke Za Zhi 2017;56:298–300. Chinese. 

28 Li J, Wang WF, Liu JH, et al. [Leukocyte chemotactic factor 2-associated renal amyloidosis coexisting with PLA2R-mediated idiopathic membranous nephropathy: report of a case]. Zhonghua Bing Li Xue Za Zhi 2021;50:532–4. Chinese.

29 Ovejero C, Cavard C, Périanin A, et al. Identification of the leukocyte cell-derived chemotaxis 2 as a direct target gene of beta-catenin in the liver. Hepatology 2004;40:167–76. 

30 Anson M, Crain-Denoyelle A-M, Baud V, et al. Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest 2012;122:586–99.

31 Buck FS, Koss MN. Hepatic amyloidosis: morphologic differences between systemic AL and AA types. Hum Pathol 1991;22:904–7.

32 Damlaj M, Amre R, Wong P, et al. Hepatic ALECT-2 amyloidosis causing portal hypertension and recurrent variceal bleeding: a case report and review of the literature. Am J Clin Pathol 2014;141:288–91. 

33 Sato Y, Watanabe H, Kameyama H, et al. Serum LECT2 level as a prognostic indicator in acute liver failure. Transplant Proc 2004;36:2359–61.

34 Okabe H, Delgado E, Lee JM, et al. Role of leukocyte cell-derived chemotaxis 2 as a biomarker in hepatocellular carcinoma. PLoS One 2014;9:e98817. 

35 Bell PD, Huber AR, DeRoche TC. Along for the ride: intrahepatic cholangiocarcinoma with concomitant LECT2 amyloidosis. Case Rep Pathol 2020;2020:1–4. 

36 Fix OK, Freise CE, Shores NJ. First liver and kidney transplant for leukocyte chemotactic factor 2-amyloidosis presenting with acute liver failure. ISN Abstract OP53. Presented at the XIII International Symposium on Amyloidosis, Groningen, The Netherlands; 6–10 May 2012. 

37 Larsen CP, Beggs ML, Wilson JD, et al. Prevalence and organ distribution of leukocyte chemotactic factor 2 amyloidosis (ALECT2) among decedents in New Mexico. Amyloid 2016;23:119–23. 

38 Eletta O, Ali M, Grieff A, et al. Clinically occult amyloidosis derived from leukocyte chemotactic factor 2 (ALECT 2) with cardiac involvement complicating renal transplantation: case report and literature review. Cardiovasc Pathol 2021;55:107375.

39 Khalighi MA, Yue A, Hwang M-T, et al. Leukocyte chemotactic factor 2 (LECT2) amyloidosis presenting as a pulmonary-renal syndrome: a case report and review of the literature. Clin Kidney J 2013;6:618–21.

40 Leung N, Ramirez-Alvarado M, Nasr SH, et al. Detection of ALECT2 amyloidosis by positron emission tomography-computed tomography imaging with florbetapir. Br J Haematol 2017;177:12. 

41 Sethi S, Theis JD, Shiller SM, et al. Medullary amyloidosis associated with apolipoprotein A-IV deposition. Kidney Int 2012;81:201–6. 

42 von Hutten H, Mihatsch M, Lobeck H, et al. Prevalence and origin of amyloid in kidney biopsies. Am J Surg Pathol 2009;33:1198–205. 

43 Chandan VS, Shah SS, Lam-Himlin DM, et al. Globular hepatic amyloid is highly sensitive and specific for LECT2 amyloidosis. Am J Surg Pathol 2015;39:558–64. 

44 Shamir ER, Lee MM, Walavalkar V. De novo leukocyte chemotactic factor 2 amyloidosis in a pediatric renal allograft, 15 years post-transplant. Pediatr Transplant 2019;23:e13371.

45 Mejia-Vilet JM, Cárdenas-Mastrascusa LR, Palacios-Cebreros EJ, et al. LECT2 amyloidosis in kidney transplantation: a report of 5 cases. Am J Kidney Dis 2019;74:563–6. 

46 Said SM, Sethi S, Valeri AM, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol 2013;8:1515–23. 

47 Paueksakon P, Fogo AB, Sethi S. Leukocyte chemotactic factor 2 amyloidosis cannot be reliably diagnosed by immunohistochemical staining. Hum Pathol 2014;45:1445–50.

Ask for more: david.deng@wecistanche.com  WhatApp:86 13632399501